SCHEMBL3014904

SCHEMBL3014904

Cc1cc(C)c(S(=O)(=O)C2CCN(c3nc(Cc4cc(C)ccc4C)cs3)CC2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.38
DNM1L O00429 12/20 0.35
NR3C1 P04150 1/20 0.35
NR3C2 P08235 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002702 0.91 AR (0.37) ARDNM1LSMN1; SMN2NPC1RAB9A
SCHEMBL3015404 0.90 AR (0.36) ARDNM1LSMN1; SMN2NPC1RAB9A
SCHEMBL3013987 0.90 DNM1L (0.37) DNM1LNR3C1NR3C2SMN1; SMN2NPC1
SCHEMBL3011496 0.89 GBA1 (0.42) ARDNM1LSMN1; SMN2NPC1RAB9A
SCHEMBL3015242 0.89 AR (0.39) ARDNM1LSMN1; SMN2NPC1RAB9A
SCHEMBL3016483 0.88 SMN1; SMN2 (0.39) ARDNM1LSMN1; SMN2NPC1RAB9A
SCHEMBL3017445 0.87 MEN1 (0.40) DNM1LSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL3006144 0.87 NR3C1 (0.37) DNM1LNR3C1NR3C2SMN1; SMN2NPC1
SCHEMBL3013654 0.87 DRD2 (0.39) ARDNM1LSMN1; SMN2NPC1RAB9A
SCHEMBL3007243 0.87 MAPT (0.36) ARDNM1LSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885DNM1L 180/4885NR3C1 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.